Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-008: pembrolizumab + lenvatinib versus docetaxel in previously treated metastatic NSCLC
2022-501439-18-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib, Lenvatinib monotherapy and Docetaxel (3 arms). Primary endpoints: Overall Survival and Progression-free Survival per RECIST 1.1. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501439-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501439-18-00.